9月17日，上海凯宝涨0.16%，成交额2.49亿元。两融数据显示，当日上海凯宝获融资买入额3442.53万 元，融资偿还2390.08万元，融资净买入1052.45万元。截至9月17日，上海凯宝融资融券余额合计3.72亿 元。 截至6月30日，上海凯宝股东户数5.25万，较上期减少3.91%；人均流通股17463股，较上期增加4.06%。 2025年1月-6月，上海凯宝实现营业收入6.05亿元，同比减少27.08%；归母净利润1.22亿元，同比减少 14.20%。 分红方面，上海凯宝A股上市后累计派现15.21亿元。近三年，累计派现2.72亿元。 机构持仓方面，截止2025年6月30日，上海凯宝十大流通股东中，香港中央结算有限公司位居第五大流 通股东，持股624.21万股，相比上期减少105.38万股。南方中证1000ETF（512100）位居第六大流通股 东，持股594.53万股，相比上期增加46.06万股。华夏中证1000ETF（159845）位居第七大流通股东，持 股341.57万股，相比上期增加37.63万股。汇添富中证中药ETF（560080）位居第八大流通股东，持股 289.25万股，相比上期减 ...

Group 1 - The core viewpoint of the article highlights that Shanghai Kaibao's financial performance for the first half of 2025 shows a decline in both revenue and net profit compared to the previous year [1] - The total operating revenue for the first half of 2025 is 605 million yuan, a decrease of 27.08% year-on-year, while the net profit attributable to shareholders is 122 million yuan, down 14.2% [1] - In Q2 2025, the operating revenue is 204 million yuan, reflecting a significant decline of 42.31% year-on-year, and the net profit for the quarter is 37.66 million yuan, down 29.84% [1] Group 2 - The gross profit margin for the first half of 2025 is 81.11%, a slight decrease of 0.57% compared to the previous year, while the net profit margin has increased to 20.13%, up 17.6% year-on-year [1] - Total expenses (selling, administrative, and financial) amount to 293 million yuan, accounting for 48.52% of revenue, which is a decrease of 4.58% year-on-year [1] - The company's earnings per share (EPS) is 0.12 yuan, a decrease of 14.2% year-on-year, while the operating cash flow per share is 0.15 yuan, an increase of 21.92% [1] Group 3 - The company's return on invested capital (ROIC) for the previous year was 7.97%, indicating an average capital return, with a historical median ROIC of 8.42% over the past decade [3] - The net profit margin for the previous year was 25.45%, suggesting a high added value for the company's products or services [3] - The company's business model is primarily driven by marketing, necessitating a thorough examination of the underlying factors behind this drive [3]

Core Viewpoint - Shanghai Kaibao reported strong financial performance in the first half of 2025, with significant revenue and profit growth, alongside advancements in research and product development [1] Financial Performance - The company achieved operating revenue of 605 million yuan in the first half of 2025, with a net profit attributable to shareholders of 122 million yuan [1] - The net cash flow from operating activities was 160 million yuan, reflecting a year-on-year increase of 21.92% [1] Research and Development - In the first half of 2025, the company invested 54.41 million yuan in research and development [1] - The company obtained one invention patent, one utility model patent, and one design patent during the reporting period [1] Product Development - The company received drug registration certificates for its classic formulations, including "Guo Yi Jian Granules" and "Ling Gui Zhu Gan Decoction Granules" [1] - The "Tan Re Qing Capsules" received approval for a new indication for use in the treatment of mild symptoms related to COVID-19, such as fever, cough, and sore throat [1] - Subsidiary Xinyi Pharmaceutical obtained registration approval for "Doxofylline Tablets," further enhancing the company's product line and market competitiveness [1] Company Overview - Shanghai Kaibao is primarily engaged in the research, production, and sales of modern traditional Chinese medicine [1] - The company is recognized as a national high-tech industrialization demonstration project base for modern traditional Chinese medicine and is among the first batch of traditional Chinese medicine enterprises to pass the new GMP certification [1] - The company has established three main product lines: respiratory products represented by "Tan Re Qing Injection/Capsules," cardiovascular products represented by "Qi Shen Capsules," and digestive products represented by "Sulfapyridine Series" [1]

每经AI快讯，上海凯宝8月28日发布半年度业绩报告称，2025年上半年营业收入约6.05亿元，同比减少 27.08%；归属于上市公司股东的净利润约1.22亿元，同比减少14.2%；基本每股收益0.1166元，同比减 少14.2%。 每经头条（nbdtoutiao）——世界首例基因编辑猪肺成功移植人体 对话主要参与者：距离临床应用还有 多远？ （记者 王瀚黎） ...

智通财经APP讯，上海凯宝(300039.SZ)发布2025年半年度报告，该公司营业收入为6.05亿元，同比减少 27.08%。归属于上市公司股东的净利润为1.22亿元，同比减少14.20%。归属于上市公司股东的扣除非经 常性损益的净利润为1.17亿元，同比减少17.81%。基本每股收益为0.1166元。 ...

Core Viewpoint - Shanghai Kaibao (300039.SZ) reported a significant decline in both revenue and net profit for the first half of 2025, indicating potential challenges in its operational performance [1] Financial Performance - The company achieved a revenue of 605 million yuan, representing a year-on-year decrease of 27.08% [1] - The net profit attributable to shareholders was 122 million yuan, down 14.20% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 117 million yuan, reflecting a year-on-year decline of 17.81% [1] - Basic earnings per share stood at 0.1166 yuan [1]

截止报告期末，募集资金的使用和结余情况具体如下： 单位：元 上海凯宝药业股份有限公司 2025 年半年度募集资金存放与使用情况的专项报告 根据《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运 作》及相关格式指引的规定，上海凯宝药业股份有限公司（以下简称"公司"或"本 公司"）董事会编制了 2025 年半年度募集资金存放与使用情况的专项报告。 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会以证监许可[2009]1387 号文核准，并经深圳证券交易 所同意，公司由主承销商东吴证券有限责任公司采用网下向配售对象询价配售与网上 向社会公众投资者定价发行相结合的方式，向社会公开发行人民币普通股（A 股）股票 2,740 万股，每股发行价 38.00 元，共募集资金总额为 104,120 万元，扣除承销费和保 荐费 5,726.60 万元后的募集资金为 98,393.4 万元，扣除其他发行费用 1,017.64 万元 后，募集资金净额 97,375.76 万元。 公司对募集资金采取了专户存储制度，上述募集资金已由主承销商东吴证券有限 责任公司于 2009 年 1 ...

上海凯宝药业股份有限公司 2025 年半年度 非经营性资金占用及其他关联资金往来情况汇总表 编制单位：上海凯宝药业股份有限公司 单位：万元 汇总表第 1 页 | | | 占用方与 上市公司 | 上市公司核算 | 2025 年期 | 2025 年度占用累 | 2025 年度占用 | 2025 年度偿 | 2025 年期 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金占用方名称 | 的关联关 | 的会计科目 | 初占用资金 | 计发生金额（不 | 资金的利息(如 | 还累计发生 | 末占用资 | 占用形成原因 | 占用性质 | | | | 系 | | 余额 | 含利息） | 有) | 金额 | 金余额 | | | | 现控股股东、实际控制人及 | | | | | | | | | | | | 其附属企业 | | | | | | | | | | | | 小计 | - | - | - | - | - | - | - | - | - | - | | 前控股股东、实际控制人及 | | | | ...

上海凯宝药业股份有限公司 证券代码：300039 证券简称：上海凯宝 公告编号：2025-036 为使投资者全面了解公司的经营成果、财务状况及未来发展规划，公司《2025 年半年度报告》于 2025 年 8 月 28 日在中国证监会指定的创业板信息披露网站：巨 潮资讯网（http://www.cninfo.com.cn）上披露，敬请投资者注意查阅。 特此公告。 上海凯宝药业股份有限公司董事会 2025 年 8 月 27 日 2025 年半年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司（以下简称"公司"）第六届董事会第十次会议审 议通过了公司《2025 年半年度报告》。 ...

证券代码：300039 证券简称：上海凯宝 公告编号：2025-040 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 上海凯宝药业股份有限公司(以下简称"公司")第六届监事会第七次会议通知 于 2025 年 8 月 16 日以邮件方式送达全体监事。会议于 2025 年 8 月 27 日上午在公 司会议室以现场和通讯相结合的方式召开，会议应参会监事三名，实际参会监事三 名。本次会议的召集、召开符合《公司法》、《公司章程》、《公司监事会议事规 则》的有关规定。会议由监事会主席主持，经全体监事审议表决，通过了以下议案： 二、审议通过了《2025 年半年度募集资金存放与使用情况的专项报告》的议案 公司监事会经过认真审核，认为公司募集资金的管理、使用及运作程序符合《创 业板上市公司规范运作指引》等有关规则和公司《募集资金管理办法》的规定，募 集资金的实际使用合法、合规，不存在违反法律、法规及损害股东利益的行为。 上海凯宝药业股份有限公司 第六届监事会第七次会议决议公告 一、审议通过了《2025 年半年度报告》及《2025 年半年度报告摘要》 经全体监事认真核查认为：《 ...